Last reviewed · How we verify
GM-CSF medium
At a glance
| Generic name | GM-CSF medium |
|---|---|
| Also known as | Embryogen |
| Sponsor | Centre for Endocrinology and Reproductive Medicine, Italy |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Phase IIa Study of Vitamin D3 Tolerogenic Dendritic Cells (tolDC) for Multiple Sclerosis (PHASE2)
- Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy (PHASE2)
- A Clinical Trial Evaluating the Safety and Efficacy of Myelin-peptide Loaded tolDC as Treatment for MS (PHASE2)
- Cytokines Supplementation to Culture Media and ICSI Outcome (NA)
- Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19) (PHASE2, PHASE3)
- Effect of GM-CSF on CAPA-IVM System Success Rates in PCOS (NA)
- Adding Cytokines to In Vitro Human Culture Media to Improve Embryogenesis and Implantation (NA)
- EmbryoGen/ Blastgen for Couples With Implantation Problems or Previous Miscarriage (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |